| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MYOV | Common Stock | Purchase | $970K | +46.5K | +0.1% | $20.86 | 48.8M | Aug 20, 2021 | See Footnote | F1, F2, F3 |
| transaction | MYOV | Common Stock | Purchase | $554K | +25.1K | +0.05% | $22.13 | 48.8M | Aug 23, 2021 | See Footnote | F4, F5, F6 |
| transaction | MYOV | Common Stock | Purchase | $682K | +30.4K | +0.06% | $22.45 | 48.9M | Aug 23, 2021 | See Footnote | F4, F6, F7 |
| Id | Content |
|---|---|
| F1 | This acquisition of a total of 46,478 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). |
| F2 | The transaction was executed in multiple trades ranging from $20.32 to $21.27 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. |
| F3 | Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 48,823,283 shares of Common Stock following the acquisition on August 20, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. |
| F4 | This acquisition of a total of 55,447 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. |
| F5 | The transaction was executed in multiple trades ranging from $21.36 to $22.35 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. |
| F6 | Sumitovant directly owns 48,878,730 shares of Common Stock following the acquisition on August 23, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. |
| F7 | The transaction was executed in multiple trades ranging from $22.36 to $22.66 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. |